Stay updated with breaking news from Simone Frattasi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- IPwe Inc., a global financial technology company providing intellectual property strategy software and analytics, proudly announces A.P. Moller...
Lamar Smith says RAIA undermines AIA; Com Laude and iaidō join forces; Germany voices opposition to COVID waiver; Arvin Patel leaves IV for Nokia
Lamar Smith says RAIA undermines AIA; Com Laude and iaidō join forces; Germany voices opposition to COVID waiver; Arvin Patel leaves IV for Nokia
Feb 02, 2021 Ben Edwards In early-December, just weeks before AstraZeneca’s coronavirus vaccine began receiving regulatory approval around the world, the Cambridge-headquartered drugmaker agreed a $39-billion deal to buy US biotech firm Alexion. The size of the transaction was driven, in part, by Alexion’s pipeline of rare blood disease treatments and its blockbuster drug Soliris. Such medicines are often the driver of bumper mergers and acquisitions in the pharmaceutical industry because of the power of patents, a type of intellectual property (IP) protection that prevents others from ...